Mumbai, May 12 -- The weak performance was primarily impacted by a sharp decline in North America revenues due to lower sales of Lenalidomide and a one-time shelf stock adjustment (SSA) of Rs 450 crore related to the product. Favourable foreign exchange movements partially offset the decline.

Excluding the one-time SSA, consolidated revenues were at Rs 7,970 crore in Q4FY26, a decline of 6.3% YoY and 8.7% QoQ and Rs 34,050 billion in FY26, a growth of 4.6% YoY.

Profit before tax (PBT) dropped 90.04% YoY to Rs 199.7 crore in Q4 FY26.

EBITDA slipped 60.37% to Rs 980.7 crore in Q4 FY26 compared with Rs 2,474.9 crore in Q4 FY25. EBITDA margin contracted to 13% in Q4 FY26 as against 29.1% in Q4 FY25. Excluding the SSA impact, EBITDA margin ...